Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics

Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics

Innovative Grade US Origin Canine Beagle Plasma from Innovative Research was used in the following study:

 

Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics

Max Sauter, Philipp Uhl, Jürgen Burhenne, Walter E.Haefeli

Journal of Pharmaceutical and Biomedical Analysis
27 March 2020

Bremelanotide (Vyleesi®) is an -melanocyte-stimulating hormone analog that was recently approved for the treatment of premenopausal hypoactive sexual desire disorder (HSDD; [1]). It is a cyclic heptapeptide (sequence: Ac-Nle-cyclo[Asp-His-d-PheArg-Trp-Lys]−OH) that is cyclized via amide bonding of the side chain carboxy-function of Asp to the amino group of the side chain of Lys and acetylated at the N-terminus… Blank beagle plasma was obtained from Dunn Labortechnik GmbH (Asbach, Germany) and supplied by Innovative Research (Novi, MI, USA).

 

Related products available from Innovative Research also include: